Related Experiment Video

Updated: Aug 15, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

[The impact of coexisting diseases on the course of chronic hepatitis C]

Wiesław Kryczka1, Dorota Zarebska-Michaluk, Magdalena Chrapek

  • 1Oddział Obserwacyjno-Zakaźny, Wojewódzki Szpital Zespolony w Kielcach.

Przeglad Epidemiologiczny
|September 30, 2005
PubMed

Insights

Coexisting diseases (CD) significantly increase the risk of advanced fibrosis in chronic hepatitis C (CHC) patients. Many patients with CD also face contraindications for antiviral treatment.

Area of Science:

  • Hepatology
  • Internal Medicine
  • Viral Hepatitis Research

Background:

  • Chronic hepatitis C (CHC) is a significant global health concern.
  • Understanding factors influencing liver disease progression is crucial for patient management.
  • Coexisting diseases (CD) may impact CHC outcomes.

Purpose of the Study:

  • To investigate the association between coexisting diseases (CD) and liver disease progression in CHC patients.
  • To determine if CD independently predict advanced fibrosis (AF) in CHC.
  • To assess the impact of CD on eligibility for antiviral treatment.

Main Methods:

  • A cohort of 557 treatment-naive CHC patients was analyzed.
  • Coexisting diseases were defined as chronic conditions requiring treatment for at least 12 months prior to biopsy.
  • Advanced fibrosis (Ishak stage 3-6) was the primary outcome, assessed via multivariate analysis controlling for age, gender, transmission route, steatosis, and overweight.

Main Results:

  • Coexisting diseases were independently associated with advanced fibrosis (adjusted OR = 3.4, p < 0.0001).
  • Age over 40 and infection via medical procedures also correlated with advanced fibrosis.
  • Antiviral treatment contraindications were significantly higher in patients with CD (18.7%) compared to those without (1.1%, p < 0.0001).

Conclusions:

  • Coexisting diseases represent a significant risk factor for advanced liver fibrosis in CHC patients.
  • A substantial proportion of CHC patients with coexisting diseases have contraindications for antiviral therapy.
  • Identifying and managing coexisting diseases is essential for optimizing CHC treatment strategies.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...